256 related articles for article (PubMed ID: 19826047)
1. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.
Ye Y; McDevitt MA; Guo M; Zhang W; Galm O; Gore SD; Karp JE; Maciejewski JP; Kowalski J; Tsai HL; Gondek LP; Tsai HC; Wang X; Hooker C; Smith BD; Carraway HE; Herman JG
Cancer Res; 2009 Nov; 69(21):8482-90. PubMed ID: 19826047
[TBL] [Abstract][Full Text] [Related]
2. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
[TBL] [Abstract][Full Text] [Related]
3. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
Jiang Y; Dunbar A; Gondek LP; Mohan S; Rataul M; O'Keefe C; Sekeres M; Saunthararajah Y; Maciejewski JP
Blood; 2009 Feb; 113(6):1315-25. PubMed ID: 18832655
[TBL] [Abstract][Full Text] [Related]
4. Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome.
Qian J; Chen XX; Qian W; Yang J; Wen XM; Ma JC; Deng ZQ; Qian Z; Zhang YY; Lin J
Clin Chem Lab Med; 2014 Dec; 52(12):1859-65. PubMed ID: 25153418
[TBL] [Abstract][Full Text] [Related]
5. Methylation of CTNNA1 promoter: frequent but not an adverse prognostic factor in acute myeloid leukemia.
Chen XX; Lin J; Qian J; Qian W; Yang J; Ma JC; Deng ZQ; An C; Tang CY; Qian Z; Liu Q
Leuk Res; 2014 May; 38(5):613-8. PubMed ID: 24685333
[TBL] [Abstract][Full Text] [Related]
6. CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.
Li M; Gao L; Li Z; Sun J; Zhang H; Duan H; Ma Y; Wang C
Oncotarget; 2016 May; 7(21):31454-65. PubMed ID: 27129146
[TBL] [Abstract][Full Text] [Related]
7. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
[TBL] [Abstract][Full Text] [Related]
8. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
[TBL] [Abstract][Full Text] [Related]
9. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
10. Absence of point mutations within the AML-1 gene in patients with MDS/AML and loss of chromosome 5q or 7.
Ferrari T; Weber B; Pils S; Harbott J; Borkhardt A
Ann Hematol; 2001 Feb; 80(2):72-3. PubMed ID: 11261327
[TBL] [Abstract][Full Text] [Related]
11. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31.
Horrigan SK; Arbieva ZH; Xie HY; Kravarusic J; Fulton NC; Naik H; Le TT; Westbrook CA
Blood; 2000 Apr; 95(7):2372-7. PubMed ID: 10733509
[TBL] [Abstract][Full Text] [Related]
12. Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network.
Fang J; Barker B; Bolanos L; Liu X; Jerez A; Makishima H; Christie S; Chen X; Rao DS; Grimes HL; Komurov K; Weirauch MT; Cancelas JA; Maciejewski JP; Starczynowski DT
Cell Rep; 2014 Sep; 8(5):1328-38. PubMed ID: 25199827
[TBL] [Abstract][Full Text] [Related]
13. Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype.
Warnstorf D; Bawadi R; Schienke A; Strasser R; Schmidt G; Illig T; Tauscher M; Thol F; Heuser M; Steinemann D; Davenport C; Schlegelberger B; Behrens YL; Göhring G
Genes Chromosomes Cancer; 2021 Jun; 60(6):452-457. PubMed ID: 33486841
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of the 5q- chromosome.
Nagarajan L
Leuk Lymphoma; 1995 May; 17(5-6):361-6. PubMed ID: 7549826
[TBL] [Abstract][Full Text] [Related]
15. Submicroscopic deletions in 5q- associated malignancies.
Crescenzi B; La Starza R; Romoli S; Beacci D; Matteucci C; Barba G; Aventin A; Marynen P; Ciolli S; Nozzoli C; Martelli MF; Mecucci C
Haematologica; 2004 Mar; 89(3):281-5. PubMed ID: 15020265
[TBL] [Abstract][Full Text] [Related]
16. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.
Christiansen DH; Andersen MK; Pedersen-Bjergaard J
J Clin Oncol; 2001 Mar; 19(5):1405-13. PubMed ID: 11230485
[TBL] [Abstract][Full Text] [Related]
17. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients.
Douet-Guilbert N; De Braekeleer E; Basinko A; Herry A; Gueganic N; Bovo C; Trillet K; Dos Santos A; Le Bris MJ; Morel F; Eveillard JR; Berthou C; De Braekeleer M
Leukemia; 2012 Jul; 26(7):1695-7. PubMed ID: 22290067
[No Abstract] [Full Text] [Related]
19. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
Horrigan SK; Westbrook CA; Kim AH; Banerjee M; Stock W; Larson RA
Blood; 1996 Oct; 88(7):2665-70. PubMed ID: 8839861
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.
Matsuoka A; Tochigi A; Kishimoto M; Nakahara T; Kondo T; Tsujioka T; Tasaka T; Tohyama Y; Tohyama K
Leukemia; 2010 Apr; 24(4):748-55. PubMed ID: 20130600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
